Their discoveries shed light on homochirality, a key concept in drug manufacturing
Category: Health
On October 7, 2026, the Royal Swedish Academy of Sciences announced that Henri Kagan and Kenso Soai have been awarded the Nobel Prize in Chemistry. Their research has provided solutions to a long-standing mystery in the field of chemistry: how certain molecules can exist as two mirror image forms, a phenomenon known as homochirality. This discovery is not just a scientific triumph; it holds immense implications for the pharmaceutical industry, where the ability to selectively produce one molecular form over another can mean the difference between a life-saving drug and a harmful side effect.
Soai, a 76-year-old chemist from Japan, expressed his joy during a press conference, stating, "This is the most exciting day in my life; I am very glad to share this prize with professor Henri Kagan." He received the news of his win unexpectedly, as he was out shopping at the time. Kagan, who is 95 and affiliated with Université Paris-Sud in France, was still being contacted by the Nobel committee at the time of the announcement.
Homochirality refers to the phenomenon where living organisms predominantly use only one of the two possible mirror image forms of a molecule. This puzzling occurrence has baffled scientists for over a century. The work of Kagan and Soai builds on earlier research by the 19th-century chemist Louis Pasteur, who first observed that certain substances exist in two forms that can have drastically different properties.
Heiner Linke, chair of the Nobel Committee for Chemistry, highlighted the significance of their findings, stating, "Henri Kagan and Kenso Soai have provided a solution to a chemical mystery that is over a century old: how homochirality can emerge spontaneously. The chemical reactions they have developed are spectacular." Their research has shown how specific chemical reactions can be manipulated to favor one mirror image over the other, a breakthrough that has become foundational for chemists involved in pharmaceutical synthesis.
One of the key contributions of Kenso Soai is the development of what is now known as the "Soai reaction," an autocatalytic process that allows for the selective production of one enantiomer, or mirror image, of a molecule. This reaction has been described as one of the most remarkable chemical experiments ever conducted.
As Kagan noted, the implications of their work extend beyond theoretical chemistry. "Many of the drug molecules occur in two variants that are each other's non-identical mirror image: one has the therapeutic effect, and the other can cause unnecessary and sometimes harmful side effects," he explained. This means that the ability to control which version is produced can lead to safer and more effective medications.
The Nobel Prize in Chemistry is often awarded for work that advances scientific knowledge and has practical applications. In this case, Kagan and Soai's research addresses a fundamental question that has implications for drug design and manufacturing, making their recognition particularly timely.
Interestingly, this year's award was somewhat unexpected. Neither Kagan nor Soai had been widely predicted to win, and their names did not appear on many lists of potential laureates. Kagan had not published any new research since 2014, and Soai's last paper came out in 2024. Nonetheless, their contributions to asymmetric organic synthesis have now been acknowledged at the highest level.
Established in the will of Alfred Nobel, the Nobel Prizes have been awarded since 1901 for achievements in various fields, including science, literature, and peace. The chemistry prize is typically the third to be announced during Nobel week, following those for medicine and physics. This year, Kagan and Soai will share a prize of 12 million Swedish kronor (approximately $1.2 million), along with the fame that comes with winning one of the world's most prestigious science awards.
The award ceremony is scheduled for December 10, the anniversary of Alfred Nobel's death, and will take place in Stockholm. The laureates will receive their medals from King Carl XVI Gustaf of Sweden, followed by a banquet at Stockholm City Hall.
Henri Kagan, who is now among the oldest Nobel laureates, has a rich academic history that includes mentorship from notable chemists like Jean Jacques and Marcel Delépine. His work has had a lasting impact on the field, particularly in the area of asymmetric catalysis, a related domain that has seen him previously recognized with prestigious awards such as the Wolf Prize.
Kenso Soai, on the other hand, is celebrated for his innovative approaches to chemical reactions, securing his place in history with the Soai reaction. His contributions have earned him accolades like the Chirality Medal in 2005, though this is his first Nobel Prize. The duo’s collaboration marks a moment of triumph not just for them personally, but for the scientific community at large, as their work continues to influence the future of drug development.
As the world looks forward to the upcoming ceremony, the legacy of Kagan and Soai's work will undoubtedly inspire future generations of chemists and researchers. Their discoveries are a reminder of the importance of fundamental research in unlocking the mysteries of chemistry and enhancing the quality of life through improved pharmaceuticals.